ImaginAb Inc. and DongCheng Pharmaceutical Group Announce Plans for a CD8 ImmunoPET Commercial Partnership
Both organizations working together to form a commercial partnership to launch ImaginAb’s CD8 ImmunoPET technology into the Greater China market
Los Angeles (USA) and Yantai (China) – January 26th, 2022. ImaginAb, a market leading global biotechnology company, focused on developing next generation immuno-oncology imaging agents and therapeutic radiopharmaceuticals (RPT), is pleased to announce it is working with DongCheng Pharmaceutical Group, to form a commercial partnership to bring ImaginAb’s CD8 ImmunoPET agent, zirconium Zr 89 crefmirlimab berdoxam product, into the Greater China market. While zirconium Zr 89 crefmirlimab berdoxam will be initially used in third party sponsored clinical trials, the goal will be to achieve market authorization.